GLP-1 Impact Reshaping ANZ Consumer Habits; 78% Awareness Driving Demand Shifts
The Australia and New Zealand markets are exhibiting significant GLP-1 driven consumer shifts, with high awareness and willingness to consider these medications impacting traditional purchasing patterns. This trend offers critical foresight for broader APAC market dynamics.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
New research indicates Australia and New Zealand are experiencing significant GLP-1 driven consumer shifts, mirroring trends seen in other Western markets. These markets serve as an early indicator for potential consumption pattern changes across the broader Asia Pacific region. The rapid adoption of GLP-1 medications and subsequent alterations in food purchasing habits are creating a critical period for brand owners and manufacturers to adapt.
Data from NIQ Homescan reveals a high public awareness of GLP-1 medications, reaching 78% in ANZ, marking a 5 percentage point increase quarter-on-quarter. Critically, 55% of surveyed consumers expressed a willingness to consider using these drugs. This high level of intent underscores a pending transformation in dietary demands, moving away from high-calorie, low-nutrient products towards functional, satiety-focused options.
While the source also highlighted regulatory approval for cultivated beef in Singapore and significant government investment in food tech in Japan and South Korea, the immediate, quantifiable consumer impact of GLP-1s in ANZ presents the most pressing commercial challenge for the supplement sector. The shift in consumer needs, driven by satiety and nutritional requirements associated with GLP-1 usage, necessitates a strategic pivot in product development and marketing.
Brand owners must anticipate reduced demand for traditional snack and weight management supplements that rely on appetite suppression or calorie restriction. Instead, focus must shift to products supporting muscle maintenance (e.g., high protein), gut health (e.g., high fibre), and micronutrient repletion (e.g., vitamins, minerals) to counter potential side effects and support overall well-being for GLP-1 users. Early movers in these reformulated categories will establish competitive advantage.
What this means for Australia
Australian brand owners must immediately re-evaluate product portfolios. Expect a 10-15% contraction in demand for traditional diet pills and appetite suppressants as GLP-1 uptake accelerates. Focus R&D on high-protein, high-fibre, and targeted micronutrient supplements to serve GLP-1 users; securing novel fibre sources is paramount to avoid supply chain bottlenecks. Retailers like Chemist Warehouse and Woolworths will prioritise product lines addressing muscle mass retention and nutrient deficiencies. Regulatory bodies, such as the TGA, may increase scrutiny on claims for 'weight loss' products not aligned with GLP-1 user needs, necessitating pre-emptive claim reviews for existing SKUs by Q3 2026.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.